CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168
2024年8月15日 - 5:00PM
CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical
company dedicated to improving the lives of patients with cancer
and inflammatory diseases by developing novel, first-in-class,
small molecules targeting Uracil-DNA metabolism, today announced
the successful dosing of the second patient in its Phase 1a study
evaluating CV6-168 + infusional 5-fluorouracil (5-FU) in cancer
patients.
This Phase 1 part of this modular, first-in-human Phase 1a
clinical trial (ISRCTN12434145) is a multicenter, open-label,
dose-escalation study of CV6-168 in patients with advanced
metastatic solid tumors refractory to standard treatment. The
primary objectives of the study are to determine the following
parameters for CV6-168: safety profile, potential optimal
biologically relevant doses, maximum tolerated dose, and anti-tumor
activity.
“CV6-168 induces DNA Uracilation, a novel mechanism of action,
and is our first drug candidate to enter the clinic. CV6-168 has
the potential to treat a variety of commonly occurring cancers in
combination with cornerstone therapies that are used to treat
millions of patients per year globally,” said Dr Robert D. Ladner,
founder, and chief executive officer at CV6. “CV6-168 accelerates
the translation of Uracil-DNA biology by inducing the
misincorporation of uracil into cancer cell DNA resulting in
uracil-repair-mediated DNA damage, immune modulation and cell death
into clinical applications. The dosing of the second patient in our
first clinical trial marks an important milestone as CV6 works to
deliver new and effective first-in-class small molecules with a
novel mechanism of action to patients facing common,
difficult-to-treat cancers.”
CV6-168 is a novel, targeted, small molecule, dUTPase-specific
inhibitor in development for the treatment of multiple,
high-incidence cancers. In preclinical studies, it has demonstrated
robust anti-tumor activity in cell line and animal models with no
added toxicity. CV6-168 targets the nucleotide metabolism enzyme
dUTPase, with high specificity, avoiding drug-drug interactions
with its drug combination partners that include thymidylate
synthase (TS) inhibitors like 5-fluorouracil (5-FU).
About CV6 Therapeutics
CV6 is a clinical-stage biopharmaceutical company focused on the
development and commercialization of novel therapeutic agents for
patients with cancer and inflammatory diseases. CV6 develops
innovative, first-in-class therapies with a novel mechanism of
action by targeting dUTPase and Uracil-DNA Metabolism - an area of
research that its founder helped pioneer. Its lead oncology drug
candidate CV6-168 is in a Phase 1a clinical trial in advanced
cancers.
Investors include QUBIS, the commercialization arm of Queen’s
University in Belfast, Invest Northern Ireland, CoFund NI, managed
by Clarendon Fund Managers, and Techstart Ventures, as well as US,
UK, European, and Australian-based private investors.
CV6 is headquartered in Belfast, Northern Ireland, UK, with
research facilities at Queen’s University Belfast in the Patrick G
Johnston Centre for Cancer Research.
For additional information, please visit CV6’s website
at www.cv6t.com and follow us on
Linkedin.
Media Contacts
CV6 Therapeutics
Dr Robert Ladner, CEO +44 (0) 7500
444287 rladner@cv6t.com
Scius Communications
Katja Stout+447789435990katja@sciuscommunications.com
Daniel Gooch+447747875479daniel@sciuscommunications.com